These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32239144)

  • 1. Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics.
    Skonieczna-Żydecka K; Łoniewski I; Stachowska E; Marlicz W; Correll CU
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):491-495. PubMed ID: 32239144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.
    Devlin AM; Panagiotopoulos C
    Pharmacogenomics; 2015; 16(9):981-96. PubMed ID: 26107755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.
    Skonieczna-Żydecka K; Łoniewski I; Misera A; Stachowska E; Maciejewska D; Marlicz W; Galling B
    Psychopharmacology (Berl); 2019 May; 236(5):1491-1512. PubMed ID: 30460516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases.
    Schiattarella GG; Sannino A; Esposito G; Perrino C
    Trends Cardiovasc Med; 2019 Apr; 29(3):141-147. PubMed ID: 30126689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health.
    Chambers ES; Preston T; Frost G; Morrison DJ
    Curr Nutr Rep; 2018 Dec; 7(4):198-206. PubMed ID: 30264354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiometabolic adaptations and benefits of recreational group sports.
    Frediani JK; Krustrup P; Lobelo F
    Prog Cardiovasc Dis; 2020; 63(6):707-708. PubMed ID: 33328097
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches.
    Shamshoum H; Medak KD; Wright DC
    Behav Brain Res; 2021 Feb; 400():113049. PubMed ID: 33290757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents.
    Bretler T; Weisberg H; Koren O; Neuman H
    BMC Med; 2019 Jun; 17(1):112. PubMed ID: 31215494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues.
    Matera E; Margari L; Palmieri VO; Zagaria G; Palumbi R; Margari F
    J Clin Psychopharmacol; 2017 Jun; 37(3):302-309. PubMed ID: 28338545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome, trimethylamine N-oxide, and cardiometabolic disease.
    Tang WH; Hazen SL
    Transl Res; 2017 Jan; 179():108-115. PubMed ID: 27490453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent Fasting Improves Cardiometabolic Risk Factors and Alters Gut Microbiota in Metabolic Syndrome Patients.
    Guo Y; Luo S; Ye Y; Yin S; Fan J; Xia M
    J Clin Endocrinol Metab; 2021 Jan; 106(1):64-79. PubMed ID: 33017844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota and probiotic intervention as a promising therapeutic for pregnant women with cardiometabolic disorders: Present and future directions.
    de Brito Alves JL; de Oliveira Y; Carvalho NNC; Cavalcante RGS; Pereira Lira MM; Nascimento LCPD; Magnani M; Vidal H; Braga VA; de Souza EL
    Pharmacol Res; 2019 Jul; 145():104252. PubMed ID: 31054952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual dimorphism of cardiometabolic dysfunction: Gut microbiome in the play?
    Cross TL; Kasahara K; Rey FE
    Mol Metab; 2018 Sep; 15():70-81. PubMed ID: 29887245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
    Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.